DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

DongKoo Bio & Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	235,784	248,515	215,064	194,496	155,131	139,216
Other Revenue	2,604	760.23	622	491.86	17.86	-
Revenue	238,388	249,275	215,686	194,988	155,149	139,216
Revenue Growth (YoY)	-6.04%	15.57%	10.62%	25.68%	11.45%	37.67%
Cost of Revenue	94,906	97,396	83,610	77,128	62,812	58,673
Gross Profit	143,482	151,879	132,076	117,860	92,337	80,543
Selling, General & Admin	126,443	129,706	105,675	91,394	72,852	60,016
Research & Development	9,799	8,380	10,752	8,258	10,114	10,751
Amortization of Goodwill & Intangibles	185.74	182.86	144.88	124.77	109.81	84.57
Other Operating Expenses	289.9	375.81	203.67	273.54	282.42	249.5
Operating Expenses	137,512	139,188	117,460	101,023	84,198	72,932
Operating Income	5,970	12,691	14,616	16,836	8,139	7,611
Interest Expense	-3,588	-2,894	-1,760	-1,039	-415.63	-430.83
Interest & Investment Income	209.45	224.42	310.5	179.43	50.88	77.57
Currency Exchange Gain (Loss)	216.9	93.19	20.79	30.37	101.41	-61.72
Other Non Operating Income (Expenses)	-321.64	505.2	287.04	956.37	4,102	473.76
EBT Excluding Unusual Items	2,487	10,619	13,474	16,963	11,978	7,670
Gain (Loss) on Sale of Investments	-1,729	-10,584	2,881	4,501	1,827	7,453
Gain (Loss) on Sale of Assets	3,432	7,114	401.74	136.72	2,258	-57.93
Asset Writedown	-4,180	-3,331	-2,016	-13,685	-4,728	-4,765
Pretax Income	9.94	3,819	14,741	7,916	11,333	10,300
Income Tax Expense	-695.07	1,828	2,932	1,302	2,007	1,160
Earnings From Continuing Operations	705.02	1,991	11,808	6,614	9,327	9,140
Minority Interest in Earnings	65.3	44.78	3.17	-	-	-
Net Income	770.31	2,036	11,812	6,614	9,327	9,140
Net Income to Common	770.31	2,036	11,812	6,614	9,327	9,140
Net Income Growth	-94.98%	-82.77%	78.59%	-29.09%	2.04%	-16.48%
Shares Outstanding (Basic)	27	27	28	28	28	28
Shares Outstanding (Diluted)	28	27	28	28	28	28
Shares Change (YoY)	1.26%	-1.13%	-0.48%	-1.78%	-0.12%	25.96%
EPS (Basic)	28.46	74.54	427.63	238.29	330.05	323.08
EPS (Diluted)	28.46	74.54	427.63	238.29	330.05	323.08
EPS Growth	-94.91%	-82.57%	79.46%	-27.80%	2.16%	-31.98%
Free Cash Flow	-18,577	-4,522	-10,260	11,841	13,637	2,221
Free Cash Flow Per Share	-668.75	-165.59	-371.44	426.63	482.57	78.50
Gross Margin	60.19%	60.93%	61.23%	60.45%	59.51%	57.86%
Operating Margin	2.50%	5.09%	6.78%	8.63%	5.25%	5.47%
Profit Margin	0.32%	0.82%	5.48%	3.39%	6.01%	6.57%
Free Cash Flow Margin	-7.79%	-1.81%	-4.76%	6.07%	8.79%	1.59%
EBITDA	14,844	19,964	20,644	22,469	13,193	12,117
EBITDA Margin	6.23%	8.01%	9.57%	11.52%	8.50%	8.70%
D&A For EBITDA	8,874	7,274	6,028	5,632	5,054	4,506
EBIT	5,970	12,691	14,616	16,836	8,139	7,611
EBIT Margin	2.50%	5.09%	6.78%	8.63%	5.25%	5.47%
Effective Tax Rate	-	47.87%	19.89%	16.44%	17.71%	11.26%
Advertising Expenses	-	2,848	1,595	1,630	1,971	3,013

Source: S&P Global Market Intelligence. Standard template. Financial Sources.